Literature DB >> 20081103

Comparative evaluation of serum markers in pulmonary sarcoidosis.

Seigo Miyoshi1, Hironobu Hamada, Toru Kadowaki, Naohiko Hamaguchi, Ryoji Ito, Kazunori Irifune, Jitsuo Higaki.   

Abstract

BACKGROUND: Although several serum markers have shown their ability to reflect lymphocytic alveolitis and disease progression in pulmonary sarcoidosis, to our knowledge no prior study has made comparative evaluations of these markers.
METHODS: Forty-three patients with pulmonary sarcoidosis were enrolled. BAL fluid (BALF) cells were analyzed, and serum levels of serum amyloid A (SAA), soluble interleukin 2 receptor (sIL-2R), lysozyme, angiotensin-converting enzyme (ACE), and the mucin-like, high-molecular-weight glycoprotein KL-6 were measured at disease presentation. Clinical data, including chest radiographs, were collected at presentation and during follow-ups. Univariate and multivariate analyses were used to identify markers best predictive of increased parenchymal infiltration.
RESULTS: Significantly higher serum levels of sIL-2R, lysozyme, and KL-6 were found in patients with parenchymal infiltration compared with those without parenchymal infiltration. The numbers of total cells and lymphocytes in BALF were significantly higher in patients with parenchymal infiltration. Serum levels of sIL-2R, lysozyme, and KL-6 were significantly correlated with the numbers of total cells, lymphocytes, and CD4(+) T lymphocytes in BALF. At the cutoff levels determined by receiver operating characteristic curves, sIL-2R, lysozyme, KL-6 serum levels, and the number of BAL lymphocytes showed significant correlations with increased parenchymal infiltrations by univariate analysis. However, multivariate analysis revealed that only KL-6 was a predictor of increased parenchymal infiltration.
CONCLUSION: Our results suggest that initial serum sIL-2R, lysozyme, and KL-6 levels may reflect lymphocytic alveolitis in pulmonary sarcoidosis. Furthermore, initial serum KL-6 tends to associate with increased parenchymal infiltration in pulmonary sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20081103     DOI: 10.1378/chest.09-1975

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  32 in total

1.  The clinical value of serum soluble interleukin-2 receptor in pulmonary sarcoidosis.

Authors:  Saiko Ogata-Suetsugu; Naoki Hamada; Koichi Takayama; Kazuya Tsubouchi; Masako Arimura-Omori; Yoichi Nakanishi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Biological role of the soluble interleukin-2 receptor in sarcoidosis.

Authors:  Remi M M Vanmaris; Ger T Rijkers
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

3.  Human chitotriosidase: a sensitive biomarker of sarcoidosis.

Authors:  Elena Bargagli; David Bennett; Claudia Maggiorelli; Pasquale Di Sipio; Maria Margollicci; Nicola Bianchi; Paola Rottoli
Journal:  J Clin Immunol       Date:  2012-08-10       Impact factor: 8.317

4.  Common patterns and disease-related signatures in tuberculosis and sarcoidosis.

Authors:  Jeroen Maertzdorf; January Weiner; Hans-Joachim Mollenkopf; Torsten Bauer; Antje Prasse; Joachim Müller-Quernheim; Stefan H E Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

5.  Elevated tenascin-C levels in bronchoalveolar lavage fluid of patients with sarcoidosis.

Authors:  Hanako Fujita; Noriho Sakamoto; Yuji Ishimatsu; Tomoyuki Kakugawa; Shota Nakashima; Shintaro Hara; Atsuko Hara; Hiroshi Mukae; Shigeru Kohno
Journal:  Lung       Date:  2012-07-04       Impact factor: 2.584

Review 6.  Diagnosis of Sarcoidosis.

Authors:  Thomas E Wessendorf; Francesco Bonella; Ulrich Costabel
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

Review 7.  Identifying Novel Biomarkers in Sarcoidosis Using Genome-Based Approaches.

Authors:  Nancy Casanova; Tong Zhou; Kenneth S Knox; Joe G N Garcia
Journal:  Clin Chest Med       Date:  2015-09-26       Impact factor: 2.878

8.  Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers.

Authors:  Gregorino Paone; Alvaro Leone; Sandro Batzella; Vittoria Conti; Francesco Belli; Laura De Marchis; Alice Mannocci; Giovanni Schmid; Claudio Terzano
Journal:  Inflamm Res       Date:  2012-12-23       Impact factor: 4.575

9.  Cathepsin S, a new serum biomarker of sarcoidosis discovered by transcriptome analysis of alveolar macrophages.

Authors:  Hiroyuki Tanaka; Etsuro Yamaguchi; Nobuhiro Asai; Toyoharu Yokoi; Masaki Nishimura; Haruhisa Nakao; Masashi Yoneda; Yoshinori Ohtsuka; Satoshi Konno; Noritaka Yamada
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

10.  Preliminary characterizations of a serum biomarker for sarcoidosis by comparative proteomic approach with tandem-mass spectrometry in ethnic Han Chinese patients.

Authors:  Yuan Zhang; Xianqiu Chen; Yang Hu; Shanshan Du; Li Shen; Yifan He; Yuxuan Zhang; Xia Zhang; Huiping Li; Rex C Yung
Journal:  Respir Res       Date:  2013-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.